The addition of tiragolumab to Tecentriq in patients with advanced PD-L1-high NSCLC failed to improve overall survival in a Phase III trial.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.Cmvv_fHs.js ...

Learn how a young woman diagnosed with stage 4 non-small cell lung cancer had many treatment options because she came to MSK first.

Susan Wojcicki, the late CEO of YouTube, had a message for the world just weeks before she passed away in August: “Lung ...

A technology has been developed that can analyze tumor mutations in lung cancer patients to confirm drug resistance to ...

Explore the challenges and advancements in anti-EGFR antibody treatment for metastatic colorectal cancer. Discover how ...

Lung cancer, a leading cause of cancer deaths, is often misunderstood. While smoking is a major risk factor, non-smokers are ...

Interestingly, the prevalence of EGFR mutations was higher in younger and female patients, whereas ALK rearrangements were ...

This week Novartis NVS upgraded its mid-term sales growth guidance. The European Commission approved Pfizer’s PFE hemophilia ...

Mumbai, Maharashtra, India Lung cancer remains one of the most prevalent and deadly cancers globally, with approximately 2.2 ...

Today marks two years since WTOP’s Neal Augenstein was diagnosed with stage 4 lung cancer. He reflects on where he’s been in ...

Metropolis molecular genomics study shows genetic profiling are improving survival rates: Our Bureau, Bengaluru Friday, November 22, 2024, 14:45 Hrs [IST] Metropolis Healthcare co ...